Form 4: Janux Therapeutics Executive Sells Shares Under 10b5-1 Plan

Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, sold shares of common stock on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Hollman Meyer, the Chief Business Officer of Janux Therapeutics, executed transactions involving the company's common stock on March 3, 2025.
• Meyer sold 2,433 shares at a weighted average price of $31.8848, with prices ranging from $31.50 to $32.25.
• An additional 901 shares were sold at a weighted average price of $32.8509, with prices ranging from $32.53 to $33.15.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on September 30, 2024.
• Meyer also exercised a stock option to acquire 3,334 shares at a price of $4.21 per share.
• Following these transactions, Meyer directly owns 82,139 shares of Janux Therapeutics common stock and 93,999 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions by an officer under a pre-existing trading plan. There's no indication of positive or negative implications for the company's performance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Key Dates